Earlier this week, Speaker of the House of Representatives Nancy Pelosi (D-CA) reached an agreement with President Donald Trump on passage of the United States-Mexico-Canada Agreement (USMCA), which if passed into law would replace the defunct and much maligned North American Free Trade Agreement (NAFTA). Not everyone is happy about the latest version of the USMCA agreed upon by the White House and House Democrats, including the U.S. Chamber of Commerce, which continues to support the overall agreement but has great concerns about the new provisions in the latest negotiated agreement between President Trump and Speaker Pelosi, which strikes expanded protection for biologic drugs from the agreement completely. Over the summer, House Democrats vocally opposed granting 10 years of regulatory data protection (RDP) for biologics inventions—an increase from 8 years in Canada and from 5 years in Mexico—arguing it would result in higher drug prices and delayed entry for biosimilars.
Business
- IPO Top 300, 2020: Slight Decreases in Patent Grants Due to Budgets, Not COVID
- Pardon Me? Levandowski Case Highlights Need for Proactive Approach to Avoid Trade Secret Problems in Hiring
- How Patents Enable Mavericks and Challenge Incumbents
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
Recent Posts
- The New Copyright Small Claims Board Presents Problems for Copyright Owners and Small Businesses
- From Home Security to VoIP: Honoring Black Women Inventors of the Last Half-Century
- Other Barks & Bites for Friday, February 26: Tillis Tells Biden to Oppose Anti-IP Efforts at WTO; China Patent Commercialization Jumps 2.5x During 13th Five-Year Plan; Federal Circuit Finds U.S. Navy Liable for Copyright Infringement
- Sarah Boone: the ‘Ironing Table’, Perfected
- How to Safeguard AI Technology: Patents versus Trade Secrets